The earnings for interest, tax, depreciation and ammortisation (EBITDA) rose 7.5% to Rs. 3179.4 crore in Q2, and EBITDA margins declined 90 basis points YoY to 26.1%. India formulation sales rose 11.1% YoY to Rs. 3843 crore in Q2FY24. India accounts for 32% of Sun Pharma sales
